Skip Navigation

Your Environment. Your Health.

Infliximab in Treatment-Refractory Juvenile Dermatomyositis

Principal Investigator:

Clarissa Pilkington, M.B.B.S.

Study Hypothesis:

Treatment refractory patients with juvenile dermatomyostiis would improve with infliximab therapy.

Study Design:

Open label

Types & Number of IIM Studied:

5 patients with juvenile dermatomyositis

Entry Criteria:

Severe or treatment resistant juvenile dermatomyositis despite treatment with at least 2 DMARD pharmacological therapies (including methotrexate) and use of intravenous methylprednisolone, and physiotherapy. Patients also had calcinosis.

IMACS Core Set Measures Included:

Physician Global Activity-VAS, Patient Global Activity-VAS, Muscle Strength Testing-MMT, Functional Assessment Tools-CMAS, CHAQ, Laboratory-Muscle Enzymes, Extramuscular Assessment-Extramuscular Global Activity, MD Assessment of Outcome

Primary Outcome:

Examined improvement in core set measures.

Secondary Outcome:

Calcinosis, joint range of motion, adverse event assessment

Key Trial Dates:


Funding Sources:

Supported by the Cathyl Hayes Research Foundation.


Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis., Rheumatology(Oxford), 2008 Jun;47(6):877-80. [Abstract]


Clarissa Pilkington, M.B.B.S.
Juvenile Dermatomyositis Research Centre
Institute of Child Health
University College of London
London, UK
Return to Studies in the Repository listing